Clinical characteristics, laboratory findings, and tolerance acquisition in infants with cow's milk protein allergy in a private center in Lima, Peru for the period 2021–2022
Immunity, Inflammation and Disease · 2024
DOI: 10.1002/iid3.1246 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Immunity, Inflammation and Disease, 2024. Verfasst von César Galván Calle und 5 weiteren Autor:innen. Beteiligte Einrichtung: Asthma Allergy and Immunology, Instituto Nacional de Salud del Niño - Breña, Breña, Lima, Peru. Hauptthemen laut MEDLINE: Milk Hypersensitivity, Immune Tolerance, Milk Proteins, Immunoglobulin E. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cow's milk protein allergy (CMPA) remains relatively understudied in Latin America.
Methods
In this observational study, we enrolled 64 patients with a median age of 3 months, of whom 60% were male. Patients included had a history of IgE‐mediated reactions with IgE sensitization or non‐IgE‐mediated reactions or symptoms following exposure to cow's milk. They underwent skin prick test, ImmunoCAP, fecal calprotectin (FC), and fecal eosinophil‐derived neurotoxin (EDN), in addition to double‐blinded placebo‐controlled oral food challenges (DBPCFC), with clinical evolution and tolerance acquisition observed over 1 year.
Results
Malnutrition was present in 78.1% of patients, and 87.5% had a family history of atopy, with 51.6% receiving exclusive breastfeeding. Gastrointestinal manifestations were prevalent in 90.6% of patients, followed by dermatological manifestations (10.9%), with only 2 experiencing anaphylaxis. IgE‐mediated CMPA was observed in only six patients. In those with non‐IgE‐mediated CMPA, FC had a median of 284 mg/dL (IQR: 138.5–415.5), while EDN had a median of 508.5 mg/dL (IQR: 160.25–868). One year after diagnosis, median FC significantly decreased ( p < 0.0001), and malnutrition prevalence reduced to 17.1%. Moreover, 81% of patients acquired tolerance following DBPCFC, with 52% utilizing nutritional replacement formulas at diagnosis. Notably, 94% of those extensively hydrolyzed casein‐based formulas achieved tolerance ( p = 0.08).
Conclusion
Our findings provide a foundational framework for future investigations into CMPA diagnosis, tolerance acquisition, and the utilization of hypoallergenic formulas tailored to the unique characteristics of our region.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Asthma Allergy and Immunology, Instituto Nacional de Salud del Niño - Breña, Breña, Lima, Peru.
- Instituto latinoamericano de Alergias, Asma e Inmunologia (ILAAI), Lince, Lima, Peru.
- Emedic Salud, San Isidro, Lima, Peru.
- Pediatrics Unit, Instituto Nacional de Salud del Niño - San Borja, San Borja, Lima, Peru.
- Clinic Laboratorio ROE, Surco, Lima, Peru.
- New York Medical College, Metropolitan Hospital, NY, USA.
ORCID-Profile: César Galván Calle, Wilmer Córdova-Calderón, Crhistian Toribio-Dionicio
Zitieren
APA
Calle, C. G., Díaz-Vásquez, C., Córdova-Calderón, W., Gómez de la Torre, J., Matos-Benavides, E., & Toribio-Dionicio, C. (2024). Clinical characteristics, laboratory findings, and tolerance acquisition in infants with cow's milk protein allergy in a private center in Lima, Peru for the period 2021–2022. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.1246
Vancouver
Calle CG, Díaz-Vásquez C, Córdova-Calderón W, Gómez de la Torre J, Matos-Benavides E, Toribio-Dionicio C. Clinical characteristics, laboratory findings, and tolerance acquisition in infants with cow's milk protein allergy in a private center in Lima, Peru for the period 2021–2022. Immunity, Inflammation and Disease. 2024. doi:10.1002/iid3.1246
BibTeX
@article{Calle2024,
author = {Calle, César Galván and Díaz-Vásquez, Cecilia and Córdova-Calderón, Wilmer and Gómez de la Torre, Juan and Matos-Benavides, Edgar and Toribio-Dionicio, Crhistian},
title = {Clinical characteristics, laboratory findings, and tolerance acquisition in infants with cow's milk protein allergy in a private center in Lima, Peru for the period 2021–2022},
journal = {Immunity, Inflammation and Disease},
year = {2024},
doi = {10.1002/iid3.1246}
}
EUVIMED